Herantis Pharma Oyj - ESG Rating & Company Profile powered by AI
This article contains a questions and answers section on Herantis Pharma Oyj. The webpage displays a zero-cost ESG report for Herantis Pharma Oyj. Alternative companies in the rating industry group for Herantis Pharma Oyj are displayed.
Herantis Pharma Oyj in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.9; made up of an environmental score of 4.0, social score of 5.3 and governance score of 5.3.
4.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 744 | Sopharma AD | 5.0 | High |
| 744 | vTv Therapeutics Inc | 5.0 | High |
| 764 | Herantis Pharma Oyj | 4.9 | High |
| 764 | BetterLife Pharma Inc | 4.9 | High |
| 764 | Acerus Pharmaceuticals Corporation | 4.9 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Herantis Pharma Oyj have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose current and historical energy intensity?
Sign up for free to unlockDoes Herantis Pharma Oyj report the average age of the workforce?
Sign up for free to unlockDoes Herantis Pharma Oyj reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose its ethnicity pay gap?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose cybersecurity risks?
Sign up for free to unlockDoes Herantis Pharma Oyj offer flexible work?
Sign up for free to unlockDoes Herantis Pharma Oyj have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Herantis Pharma Oyj conduct supply chain audits?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Herantis Pharma Oyj conduct 360 degree staff reviews?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose the individual responsible for D&I?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose water use targets?
Sign up for free to unlockDoes Herantis Pharma Oyj have careers partnerships with academic institutions?
Sign up for free to unlockDid Herantis Pharma Oyj have a product recall in the last two years?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose incidents of discrimination?
Sign up for free to unlockDoes Herantis Pharma Oyj allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Herantis Pharma Oyj issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose parental leave metrics?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose the pay ratio of women to men?
Sign up for free to unlockDoes Herantis Pharma Oyj support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Herantis Pharma Oyj reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Herantis Pharma Oyj involved in embryonic stem cell research?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose its waste policy?
Sign up for free to unlockDoes Herantis Pharma Oyj report according to TCFD requirements?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose energy use targets?
Sign up for free to unlockDoes Herantis Pharma Oyj disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Herantis Pharma Oyj have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Herantis Pharma Oyj
These potential risks are based on the size, segment and geographies of the company.
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.